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Abstract 
 
Liver failure is the major cause of death following liver resection. Post-resection 
portal venous pressure (PVP) predicts liver failure, is implicated in its pathogenesis 
and when PVP is reduced, rates of liver dysfunction decrease. The aim of this study 
was to characterize the hemodynamic, biochemical and histological changes induced 
by 80% hepatectomy in non-cirrhotic pigs and determine if terlipressin or direct 
portacaval shunting can modulate these effects. Pigs were randomized (n=8/group) 
to undergo 80% hepatectomy alone (control); terlipressin (2 mg bolus + 0.5-1 mg/h) + 
80% hepatectomy; or portacaval shunt (PCS) + 80% hepatectomy, and were 
maintained under terminal anesthesia for 8 hours. The primary outcome was change 
in PVP. Secondary outcomes included portal venous flow (PVF), hepatic arterial flow 
(HAF), and biochemical and histological markers of liver injury. Hepatectomy 
increased PVP (9.3±0.4 mm Hg pre-hepatectomy vs. 13.0±0.8 mm Hg post-
hepatectomy, p<0.0001) and PVF/g liver (1.2±0.2 ml/min/g vs. 6.0±0.6 ml/min/g, 
p<0.0001) and decreased HAF (70.8±5.0 ml/min vs. 41.8±5.7 ml/min, p=0.002). 
Terlipressin and PCS reduced PVP (terlipressin=10.4±0.8 mm Hg, p=0.046 and 
PCS=8.3±1.2 mm Hg, p=0.025) and PVF (control=869.0±36.1 ml/min vs. 
terlipressin=565.6±25.7 ml/min, p<0.0001 and PCS=488.4±106.4 ml/min, p=0.002) 
compared with control. Treatment with terlipressin increased HAF (73.2±11.3 ml/min) 
compared with control (40.3±6.3 ml/min, p=0.026). The results of this study suggest 
that terlipressin and PCS may have a role in the prevention and treatment of post-
resection liver failure. 
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Introduction 
 
Post-resection liver failure (PLF) is a devastating complication that is resource 
intensive [1], carries considerable morbidity and remains the primary cause of death 
following major liver resection [2]. Up to 90% of patients undergoing major (>50%) 
hepatectomy experience some degree of liver dysfunction [3]. This becomes clinically 
significant in half and progresses to PLF in up to 10% [2].  
 
Risk factors identified for the development of PLF include extent of resection, 
presence of underlying parenchymal disease [2], elevated post-resection portal 
venous pressure (PVP) in non-cirrhotic patients [4] and pre-resection portal 
hypertension in cirrhotic patients [5]. Allard et al. [4] demonstrated that the risk of PLF 
and dying increased when post-resection PVP in non-cirrhotic patients increased 
above a threshold of 21-22 mmHg. The risk of PLF was negligible when PVP 
remained at normal levels (≤10 mmHg).  
 
In porcine models of major liver resection, where post-resection PVP is modulated by 
portacaval shunting [6], mesocaval shunting [7, 8] or by implantation of an adjustable 
vascular ring [9], the degree of post-resection liver dysfunction is reduced. 
Performing portacaval or mesocaval shunting in patients undergoing major liver 
resection adds complexity to the procedure; may increase morbidity through 
encephalopathy [10, 11], could inhibit liver regeneration due to the diversion of 
hepatotropic factors [12] and requires an additional procedure to close the shunt 
once regeneration is complete. It is, therefore, desirable to explore strategies that 
reduce PVP without introducing additional morbidity peri/post-resection.  
 
Tri-glycyl-lysine-vasopressin (terlipressin) is metabolized in the circulation to lysine-
vasopressin, where its effects include reductions in PVP and portal venous flow 
(PVF) [13]. Terlipressin is used widely to treat complications of portal hypertension in 
patients with cirrhosis. It reduces rebleeding following acute variceal hemorrhage [14, 
15]; improves renal recovery in hepatorenal syndrome [16-20]; and reduces PVF 
following split graft liver transplantation [21]. Recent studies have also explored its 
effects after hepatectomy in rodents. Terlipressin reduced PVP following 90% 
hepatectomy [22], but had no effect on liver regeneration after 70% hepatectomy in 
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rats [23]. In mice, terlipressin reduced PVP and increased liver regeneration after 
partial hepatectomy [24]. The effects of terlipressin on PVP after major hepatectomy 
in the absence of cirrhosis in a large animal model have not been reported. 
 
The current study set out to characterize the hemodynamic, biochemical and 
histological changes induced by 80% hepatectomy in non-cirrhotic pigs in a terminal 
anesthetic model and to determine if terlipressin or direct portacaval shunting (PCS) 
could reverse these effects. We hypothesized that terlipressin and PCS would reduce 
PVP and PVF and increase hepatic artery flow (HAF) post-hepatectomy.  
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Methods 
 
Study design 
The study was undertaken in three parts: an acute pilot study, an acute non-survival 
series and a survival pilot study (Supplementary Figure 1). The acute pilot study 
provided preliminary data on hemodynamic and biochemical changes pre/post-
hepatectomy ± terlipressin or PCS, and determined the optimal terlipressin-dosing 
regimen under terminal anesthesia. 
 
The acute series compared the hemodynamic effects of terlipressin or PCS pre/post-
hepatectomy in pigs maintained under terminal anesthesia for up to 8 hours post-
hepatectomy. Pigs were randomized (sealed envelope drawn one week prior to 
surgery), to undergo hepatectomy alone (control); terlipressin followed by 
hepatectomy or PCS followed by hepatectomy. There was no sham group in this 
series. PVP, PVF, HAF and mean arterial pressure (MAP) were recorded 
continuously. Arterial and portal venous blood and liver biopsies were taken at 
intervals throughout the series. Biopsies were also collected post-mortem.  
 
In the survival pilot, pigs underwent 80% hepatectomy alone and were maintained for 
up to 7 days post-hepatectomy. There was no comparison group in the survival pilot. 
PVP and PVF were recorded and central/portal venous blood samples were taken 
daily. Biopsies were collected post-mortem. Data from the survival pilot are 
presented in the Supplementary Document. 
 
Animals 
All protocols were approved by the Norwegian Animal Research Authority, conducted 
in compliance with and presented in accordance with the National Institute of 
Health’s Guide for the Care and Use of Laboratory Animals [25]. Based on the pilot 
series we estimated that to demonstrate a 10% reduction in PVP (i.e. to reduce post-
resection PVP to <10 mmHg) with terlipressin or PCS post-hepatectomy, 8 animals 
were required per group. In total 40 castrate male Norwegian pigs (Sus scrofa 
domesticus, weight = 32.0±5.9 kg) were used: 8 in the acute pilot, 24 in the acute 
series and 8 in the survival pilot.  
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Anesthesia was administered using an established protocol developed previously 
within the group [26]. Pigs were pre-medicated with intramuscular ketamine (20 
mg/kg) and atropine (1 mg). Anesthesia was induced with intravenous fentanyl (0.01 
mg/kg) and isofluorane in oxygen (FiO2 = 0.5, Servo 900, Elema-
Schönander/Siemens, Erlangan Germany) and maintained with intravenous fentanyl 
(0.02 mg/kg/h), midazolam (0.3 mg/kg/h) and isflourane in oxygen. Ceftriaxone (2 g) 
was given post-induction. 
 
5-F catheters (CVK, Secalon T, Argon Critical Care Ltd, Singapore, Singapore) were 
placed in both internal jugular veins and left femoral artery (blood sampling and 
MAP). Intravenous fluids were delivered at 100 ml/h with boluses to maintain MAP 
>50 mm Hg, central venous pressure (CVP) 5-8 mmHg and urine output >0.5 
ml/kg/h. If refractory hypotension developed (MAP <50 mm Hg for >10 min despite 
volume replacement) norepinephrine (0.025 μg/kg/h) was commenced.  
 
Liver hemodynamic monitoring 
Laparotomy was performed through a right-sided, reverse-L incision. 3 mm flow 
probes were placed around the left and right hepatic arteries and a 12 mm flow probe 
around the portal vein (Medistim, Oslo, Norway). A 6-F double lumen catheter was 
placed directly into the portal vein (Arrow International, Reading, USA) and secured 
with 5/0 polypropylene sutures. Calibrated transducers (Transpac 3, Abbott Critical 
Care Systems, Chicago, USA) were connected to an amplifier (Gould, 2800S, Ohio, 
USA). Pulsatile signals were displayed, digitalized, and stored electronically.  
Terlipressin  
In the terlipressin group (Glypressin®, donated by Ferring Pharmaceuticals, West 
Drayton, UK), a 2 mg intravenous terlipressin bolus was given 20 min pre-
hepatectomy and an intravenous terlipressin infusion (0.5-1 mg/h) was commenced 
post-hepatectomy and continued for the duration of the experiment. No placebo was 
given in the control or PCS groups. 
Direct portacaval shunt 
In the shunt group a side-to-side direct PCS was sutured using continuous 5/0 
polypropylene on the infrahepatic portion of the inferior vena cava, as described 
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previously [6, 27] with an increase in shunt diameter from 5 mm to 8 mm. Partial 
(side) clamping of the portal vein and inferior vena cava was required during PCS 
formation. Shunt patency was confirmed by demonstrating PVF reduction following 
clamp release and by direct inspection and measurement post-mortem. Hepatectomy 
was commenced 20 min after completion of PCS.  
80% hepatectomy 
80% hepatectomy was undertaken as previously described [28, 29] with minor 
modifications. The left hepatic artery, portal vein and bile duct were ligated at the 
hilum. Segments II, III, IV, V & VIII were resected en bloc with manual control of the 
vascular pedicle. The pedicle stump was oversewn with 2/0 polyglactin. Segment VI 
was resected by manual control of the vascular VI/VII pedicle and its venous 
branches oversewn with 2/0 polyglactin, to leave segments I and VII. Resected wet 
liver weights were recorded. An estimated remnant liver weight was calculated using 
the equation: remnant liver weight (g) = 0.025 x total body weight (g) - resected liver 
weight (g).  
 
Survival pilot study 
In the survival pilot, tunneled single lumen 6-F Broviac catheters (Bard Access 
Systems Inc, Salt Lake City, USA) were placed in each internal jugular vein. The 
portal catheter and flow probe were tunneled laterally through the abdominal wall. A 
feeding gastrostomy (Cook Medical Inc., Bloomington, USA) was inserted. 
Lines/cables were secured with a protective vest (Lomir Biomedical Inc., Malone, 
USA). Fluids, analgesia and antibiotics were given daily. Blood was taken and CVP, 
PVP and PVF were recorded daily under sedation (midazolam 0.15 mg/kg) in the left-
lateral position. HAF/MAP were not recorded and no pigs received/underwent 
terlipressin/PCS in the survival series. 
 
Post-mortem 
At the end of each experiment blood, liver, spleen, small bowel and left kidney 
biopsies were collected. Probe/catheter positions were confirmed and the liver ± 
shunt were weighed/measured.  
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Biochemistry 
Serum aspartate aminotransferase (AST), bilirubin, sodium, potassium, urea, 
creatinine and plasma ammonia were measured using a cobas®c analyzer (Roche 
Diagnostics, Indianapolis, USA); international normalized ratio (INR) with an STA® 
prothrombin time assay kit (Diagnostica Stago SAS, Asnières sur Seine Cedex, 
France); serum lactate with an ABL 800 flex blood gas analyser (Radiometer Medical 
ApS, Brønshøj, Denmark); and Lysine-vasopressin with a (lysine8) vasopressin 
enzyme-linked immunosorbant assay kit (Sigma-Aldrich, St Louis, USA). 
  
Histological analysis 
Liver, small bowel, splenic and renal biopsies were divided and flash-frozen in liquid 
nitrogen and stored at -80°C or processed for histology, by fixing under vacuum in 
10% neutral-buffered formalin for 24 h at 37°C and stored for up to 1 month. 
Histology samples were paraffin-embedded on a Shandon™ Excelsior™ ES tissue 
processor (Thermo-Fisher Scientific Inc., Waltham, USA). 3 mm sections were 
stained with hematoxylin and eosin (H & E).  
 
Hemodynamic analysis 
 
Flow was compared using raw data (ml/min) and flow by liver weight (ml/min/g). The 
latter was calculated using the equation: flow/g (ml/min/g) = total flow (ml/min) / 0.005 
´ body weight (g). HAF was the sum of left and right hepatic artery flows. Data are 
expressed as the mean ± standard deviation unless otherwise stated. PVP, PVF HAF 
and MAP were analyzed with repeated-measures ANOVA, using data extracted from 
the real-time data material sampled over 10-min intervals and analyzed using IBM 
SPSS 22.0 for Mac OSX SPSS (IBM Corp., Armonk, NY). Differences were 
considered statistically significant at p <0.05.  
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Results 
 
Pilot data and the effects of terlipressin and direct PCS pre-hepatectomy 
Terlipressin and PCS reduced PVP and PVF if given/performed pre- or post-
hepatectomy. To standardize the approach between groups, terlipressin-dosing and 
PCS were undertaken pre-hepatectomy. The pigs were maintained for up to 8 hours 
post-hepatectomy, because in the acute pilot experiments there was typically a 
progressive deterioration in physiological parameters beyond 8 hours. 
 
Following 2 mg terlipressin pre-hepatectomy, PVP remained stable (Figure 1A), PVF 
decreased (Figure 1B) and HAF increased (Figure 1C). Following PCS, PVP and 
PVF decreased and HAF increased. PCS patency was confirmed by a reduction in 
PVF from 988±296 ml/min to 715±252 ml/min. The reduction was similar between 
animals. There were no differences in PVP, PVF or HAF between the terlipressin and 
PCS groups. MAP increased after terlipressin. PCS had no effect on MAP pre-
hepatectomy (Figure 1D). 
 
The segment II, III, IV, V & VIII resection resulted in a 78.9±2.3 % hepatectomy, with 
an additional cuff of devascularized parenchyma at the base of segments II/VIII. The 
average time for hepatectomy was 37±8 min. The average shunt diameter measured 
at post-mortem was 8±1 mm.  
 
The effects of hepatectomy on liver and systemic hemodynamics and 
biochemistry 
In the control group, PVP increased post-hepatectomy and remained elevated 
throughout the experiment (Figure 2A). There was no change in PVF post-
hepatectomy (Figure 2B) although the PVF/g increased (Figure 2C). HAF 
decreased post-hepatectomy and remained lower throughout the experiment (Figure 
2D). 
 
In the PCS group 4 pigs developed refractory hypotension within 3 hours of 
hepatectomy necessitating norepinephrine. One pig in the control group required 
norepinephrine after 3 hours. Norepinephrine was not required in the terlipressin 
group. CVP was maintained between 5-8 mm Hg and urine output >0.5 ml/kg/h 
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throughout the experiment. Urine output increased in the terlipressin group versus 
control and PCS groups.  
 
Figure 3 (A-D) summarizes the biochemistry from the acute series. Sodium, 
potassium, urea and creatinine (not shown) remained within normal limits in all 
groups throughout the series. Bilirubin (Figure 3A), lactate (Figure 3B), INR and 
AST increased in all groups but no differences were detected between groups. 
Ammonia increased in all groups and was greater in the PCS group at 3 hours 
versus control (Figure 3C). Lys-vasopressin was detected in all groups. Levels 
remained at baseline in the control and PCS groups and increased in the terlipressin 
group (Figure 3D). 
 
In the survival pilot 80% hepatectomy was undertaken with 100% 1-day and 62% 3-
day survival. The pigs experienced significant morbidity (pain and ascites) post-
hepatectomy. PVP increased and remained elevated up to day 5 post-hepatectomy 
(Supplementary Figure 2A). PVF initially decreased post-hepatectomy, then by 12 
hours PVF had increased from baseline and remained elevated up to day 5 
(Supplementary Figure 2B). HAF was not measured in the survival experiments. 
Serum sodium, potassium and urea were within normal limits throughout the survival 
pilot. Serum creatinine increased on day 1, and returned to baseline by day 2. Serum 
bilirubin (Supplementary Figure 2C) peaked on day 2. INR (Supplementary Figure 
2D), AST (Supplementary Figure 2E), and ammonia (Supplementary Figure 2F) 
peaked on day 1. INR normalized by day 4. Bilirubin, AST and ammonia remained 
elevated throughout the survival pilot.  
 
The effects of terlipressin and PCS on PVP post-hepatectomy 
Figure 4A traces the median PVP for three representative 10 min intervals for each 
group: baseline; pre-hepatectomy but post-terlipressin/PCS; and post-hepatectomy. 
There were no differences in baseline PVP between groups. PVP increased post-
hepatectomy from baseline and remained elevated for the duration of the study. 
There was no difference in baseline and post-hepatectomy PVP in the terlipressin 
and PCS groups for the duration of the study. 
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Figure 4 (B-E) summarizes the mean PVP of representative 10 intervals sampled 
immediately post-hepatectomy and hourly throughout the acute series. Terlipressin 
reduced post-hepatectomy PVP within 1 hour and its effects were sustained 
throughout the series when compared with the control group and not within the 
terlipressin group. PCS reduced post-hepatectomy PVP for up to 4 hours post-
hepatectomy when compared with the control group and not within the PCS group. 
There was no difference in PVP between the terlipressin and PCS groups throughout 
the series. 
 
 
The effects of terlipressin and PCS on PVF post-hepatectomy 
Figure 5A traces the median PVF for each group and study interval. There were no 
differences in pre/post-hepatectomy PVF in the control, terlipressin (p=0.84) or PCS 
(P=0.21) groups. PVF/g increased in all groups post-hepatectomy (not shown). 
 
Figure 5 (B-E) summarizes the mean PVF for representative intervals sampled over 
the post-hepatectomy period. Terlipressin and PCS led to reductions in PVF 
throughout the series post-hepatectomy when compared with the control group and 
not within the terlipressin nor the PCS groups. There were no differences in PVF 
between the terlipressin and PCS groups throughout the series.  
 
The effects of terlipressin and PCS on HAF post-hepatectomy 
Figure 6A traces the median HAF for each group and study interval. HAF decreased 
in the hepatectomy alone, terlipressin (p=0.003) and PCS (p=0.024) groups post-
hepatectomy. 
 
Figure 6 (B-E) summarizes the mean HAF for representative intervals sampled over 
the post-hepatectomy period. Immediately post-hepatectomy HAF in the terlipressin 
group exceeded HAF in the PCS group but not the control. After one hour HAF in the 
terlipressin group was greater than control and remained higher for up to 7 hours 
post-hepatectomy. HAF in the terlipressin group also exceeded that of the PCS 
group for prolonged intervals post-hepatectomy. There was no difference in HAF 
between the PCS and control groups throughout the series.  
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Histology 
There were variations in the baseline liver tissue within and between groups, in terms 
of steatosis, hepatocyte staining, sinusoidal diameter, and presence of intra-
sinusoidal mononuclear cells. All groups demonstrated extravasation of red cells 2 
hours post-hepatectomy with progressive portal edema (Supplementary Figure 3A) 
and neutrophil migration appearing 6 hours post-hepatectomy. The extent of red cell 
extravasation and portal edema in the pigs receiving terlipressin was reduced at the 
later time points compared with the control pigs. No proliferative markers were 
assessed in this acute study. It was not possible to quantify these differences using 
image analysis. No evidence of splenic, kidney or small bowel pathology was 
detected across the acute series.  
 
In the survival pilot, up to 3 days post-hepatectomy post-mortem liver histology 
demonstrated variable venous congestion, sinusoidal dilatation, and sinusoidal 
mononuclear cell infiltration. No biliary changes were demonstrated up to day 3. 
There was evidence of hepatocyte and non-parenchymal cell regeneration. From 
days 4-7 sinusoidal dilatation and venous congestion persisted. In addition, there 
was evidence of inflammation, biliary injury [desquamation and infarction 
(Supplementary Figure 3B)] and steatosis (Supplementary Figure 3C). 
Regenerative changes were less evident than in earlier post-mortem specimens. All 
splenic biopsies from the survival pilot demonstrated venous congestion. Small bowel 
biopsies demonstrated bowel wall thickening. There was no evidence of kidney 
pathology.  
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Discussion 
 
This study demonstrates that 80% hepatectomy in the pig increases PVP and PVF/g 
and reduces HAF, and that terlipressin and PCS attenuate these effects in a terminal 
anesthetic model. Although previous studies have demonstrated the effects of PCS 
on liver hemodynamics post-hepatectomy in pigs [6, 7] and of terlipressin post-
hepatectomy in rodents [22-24], this is the first study to report the effects of 
terlipressin on liver hemodynamics post-hepatectomy in a non-cirrhotic porcine 
model. 
 
The effects of terlipressin and PCS were characterized using a terminal anesthetic 
model, previously developed within our group [30-32]. This enabled multiple, 
continuous pressure and flow measurements to be recorded simultaneously whilst 
minimising morbidity in the study group. Whilst it is feasible to measure liver and 
systemic hemodynamics at intervals post-hepatectomy in a survival setting [7, 29], in 
our experience there is greater variability in PVP and PVF between pigs (due to the 
physiological instability that accompanies the ensuing PLF) and the animals are 
exposed to significant morbidity. The terminal anesthetic model allowed us to 
demonstrate continuous real-time physiology in the early phase post-hepatectomy. 
The limitation of this model is that it does not enable characterisation of liver 
hemodynamics beyond 8 hours. 
 
In the survival pilot, after 80% hepatectomy PVP and PVF changes were sustained 
for 5 days and accompanied by significant liver dysfunction. This clinical course was 
comparable with existing studies [29]. Histology one-week post-hepatectomy 
demonstrated hepatic sinusoidal dilatation, venous congestion, steatosis and 
inflammation within a regenerating liver. There are limited reports of histological 
changes in pig liver after extended hepatectomy. Similar patterns may be observed in 
patients that develop small-for-size syndrome after split-liver transplantation, where 
liver biopsies taken within the first 10 days post-transplantation demonstrate venous 
congestion, sinusoidal injury, steatosis and cholestasis [33]. With the exception of 
cholestasis (often a later change), these features were present in the survival pilot.  
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Previous studies have demonstrated that 80% hepatectomy in the pig increases 
PVP, leads to liver dysfunction and increases mortality [29]. In this terminal 
anesthetic study, 80% hepatectomy led to a PVP increase. Both terlipressin and PCS 
maintained PVP at pre-resection levels after 80% hepatectomy for the duration of the 
study. In addition, post-hepatectomy PVP was significantly lower than in the control 
group for up to 4 hours in the PCS group and up to 6 hours in the terlipressin group. 
If this effect was sustained in a survival model, terlipressin and PCS could have an 
impact on rates of liver dysfunction. 
The post-hepatectomy PVP increase in pigs is less than the PVP increase following 
equivalent resections in patients [4], although their clinical course is comparable [29]. 
The difference in post-hepatectomy PVP between pig and human liver may be 
explained by variations in parenchymal compliance, venous outflow and the 
presence of unreported parenchymal disease in patients undergoing major 
hepatectomy. The cause for variation in baseline tissue is unknown, but was not 
thought to have impacted on differences in liver hemodynamics between groups, as 
the pigs were randomized pre-operatively and there was no fibrosis or cirrhosis 
detected in the baseline liver biopsies. 
 
The hepatic artery buffer response autoregulates liver blood flow. When PVF 
increases, HAF decreases and vice versa [34, 35]. This was demonstrated pre-
hepatectomy in normal liver where both terlipressin and PCS reduced PVF resulting 
in an increase in HAF [7].  
 
Post-hepatectomy terlipressin reduced PVF and increased HAF compared with the 
control group. Vasopressin exerts a biphasic response on HAF. If infused directly into 
the hepatic artery vasopressin leads to hepatic artery vasoconstriction. When it is 
given systemically, vasopressin causes splanchnic vasoconstriction; reducing PVF, 
which in turn increases HAF, through the buffer response [36]. PCS reduced PVF 
and increased HAF pre-hepatectomy. Post-hepatectomy no difference in HAF was 
demonstrated when compared with control. Interpretation of the hemodynamic 
effects of PCS on HAF is difficult because 50% of pigs in the PCS group required 
norepinephrine, which is likely to have had a direct vasoconstrictive effects on the 
hepatic artery [37].  
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The decreased oxygen delivery that results from HAF reduction, together with the 
venous congestion that arises from increasing PVF/g, may induce hypoxia in the 
remnant liver, precipitating a cycle of inflammation and impaired regeneration, which 
could exacerbate liver dysfunction. This process may have parallels with ischemia-
reperfusion injury [38]. 
 
80% hepatectomy + PCS caused hemodynamic instability that required 
supplementary fluids and norepinephrine 3-4 hours post-hepatectomy. No pigs 
receiving terlipressin required norepinephrine. MAP increased significantly following 
administration of terlipressin. It is likely that terlipressin-induced arteriolar 
vasoconstriction augmented MAP, however the absence of information regarding 
cardiac index or vascular resistance, limits the ability to distinguish true terlipressin-
induced changes. 
 
Direct PCS was used as this had previously been demonstrated to modulate liver 
dysfunction in pigs after major hepatectomy [6]. The increased hemodynamic 
instability in the PCS group was an unexpected finding. Whilst the duration of partial 
portal clamping was minimized during shunt formation, portal clamping is very poorly 
tolerated in pigs and this may have contributed to instability following PCS. Future 
studies may compare the use of mesocaval shunting or use of an interposition graft 
to minimize the impact of portal clamping in this porcine model.  
 
The aim of the terlipressin-dosing regimen was to maintain stable PVP reduction. As 
lys-vasopressin is rapidly metabolized by the pig, terlipressin infusion was required to 
achieve stable PVP reduction. This contrasts with the terlipressin activity in humans, 
where clearance is slower and hence bolus terlipressin-dosing achieves stable PVP 
reduction. No direct side effects of terlipressin (renal dysfunction, hyponatremia or 
cardiovascular effects) were observed, but these should be explored in a survival 
model. 
 
Lactate and ammonia provided the most direct markers of liver dysfunction. The 
increased plasma ammonia observed in the PCS group supports concerns about 
exacerbating encephalopathy when modulating portal inflow at the time of liver 
surgery. There were no quantifiable differences in liver histology between groups. In 
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survival series, peak liver dysfunction does not occur until beyond day 1 post 
hepatectomy [29], as was demonstrated in our survival pilot. The biochemical profile 
immediately after 80% hepatectomy has not been described previously. 
 
Currently there is no established therapy to prevent/treat PLF in non-cirrhotic 
patients. PCS [6, 7], splenic artery ligation [39, 40], splenectomy [41, 42] and portal 
banding [9] have all been used to modulate post-hepatectomy PVP and prevent PLF. 
The degree and duration of PVP reduction required to prevent PLF in non-cirrhotic 
liver post-hepatectomy is unknown [4]. Whilst surgical approaches may achieve more 
pronounced/sustained PVP reduction, the additional surgical morbidity associated 
may not be justified. Reduction of post-resection PVP with terlipressin in non-cirrhotic 
patients could offer several advantages over surgical strategies because terlipressin 
does not require additional interventions (to close the shunt or remove the portal 
band) and may avoid morbidity associated with surgical PVP modulation 
(encephalopathy and circulatory dysfunction). These benefits must be balanced 
against potential adverse effects that can occur at higher terlipressin doses. A 
stepwise approach to post-resection PVP modulation could be employed. For 
example, elevated PVP could initially be treated with terlipressin then if PVP is 
refractory or terlipressin is poorly tolerated, a surgical technique could be considered.  
 
Whilst previous studies have evaluated the dose, toxicity and pharmacodynamics of 
terlipressin in cirrhotic patients [14-20], equivalent data in non-cirrhotic patients is 
limited. It is not possible to directly translate data from cirrhotic to non-cirrhotic 
patients because there are major differences in hepatic and systemic hemodynamics 
[43]. A phase 1 study is required to confirm the safe dose and initial proof of concept 
in non-cirrhotic patients post-hepatectomy.  
 
There are limitations to this study. The impact of terlipressin and PCS were evaluated 
in a terminal anesthetic study. It was, therefore, not possible to determine the effects 
of terlipressin or PCS on PLF/survival. The late hemodynamic instability that 
developed in the PCS group limits the ability to compare PCS and terlipressin. The 
mechanism for this instability is uncertain but may reflect the impact of partial portal 
clamping duration shunt formation. 
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The anesthetic agents are likely to have caused fluctuations in liver hemodynamics. 
However the anesthetic protocol was developed to minimize hemodynamic changes 
within the liver and was standardized between groups. Future studies examining the 
impact of terlipressin/PCS on PLF will be undertaken in a survival series. This paper 
has not presented detailed characterization of the pathogenesis of liver injury. 
Subsequent studies will examine differences in immunohistochemistry and gene 
expression between groups.  
 
In conclusion the PVP and PVF reduction induced by terlipressin and PCS post-
hepatectomy, suggests these interventions may have a role in in the 
prevention/treatment of PLF. Further evaluation should be undertaken in the setting 
of a survival series and multicenter controlled trial. 
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Figures 
 
Fig. 1. The effects of terlipressin and direct portacaval shunt (PCS) on portal 
venous pressure (PVP), portal venous flow (PVF), hepatic artery flow (HAF) and 
mean arterial pressure (MAP) in normal liver (prior to 80% hepatectomy). 
Values represent mean ± standard deviation, n=8 per group. * p<0.05 compared with 
control (pre-terlipressin or pre-PCS) PVP, PVF, HAF or MAP. (A) The effects of 
terlipressin or PCS on PVP in normal liver. Control vs terlipressin, p=0.11. Control vs. 
PCS, p=0.009. (B) The effects of terlipressin or PCS on PVF in normal liver. Control 
vs. terlipressin, p=0.003. Control vs. PCS, p=0.017. (C) The effects of terlipressin or 
PCS on HAF in normal liver. Control vs. terlipressin, p=0.001. Control vs. PCS, 
p=0.012. (D) The effects of terlipressin or PCS on MAP prior to hepatectomy. Control 
vs. terlipressin, p<0.0001. Control vs. PCS, p=0.80. 
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Fig. 2. The effects of 80% hepatectomy on portal venous pressure (PVP), portal 
venous flow (PVF) (by liver weight) and hepatic artery flow (HAF) were 
assessed 30 min post-hepatectomy. Values represent mean ± standard deviation, 
n=8 per group. * p<0.05 compared with pre-hepatectomy PVP, PVF, PVF by liver 
weight or HAF. (A) The effects of 80% hepatectomy on PVP. Pre vs. post, p<0.0001. 
(B) The effects of 80% hepatectomy on PVF. Pre vs. post, p=0.22. (C) The effects of 
80% hepatectomy on PVF by liver weight. Pre vs. post, p<0.0001. (D) The effects of 
80% hepatectomy on HAF. Pre vs. post, p=0.002.  
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Fig. 3. Serum bilirubin, serum lactate, plasma ammonia and serum lys-
vasopressin at 3 hours post hepatectomy. Values represent mean ± standard 
deviation, n=8 per group. * p<0.05 compared with control (hepatectomy alone) 
bilirubin, lactate, ammonia or terlipressin. (A) Bilirubin at 3 hours post-hepatectomy. 
Control vs. terlipressin, p=0.18. Control vs. portacaval shunt (PCS), p=0.31. (B) 
Lactate at 3 hours post-hepatectomy. Control vs. terlipressin, p=0.37. Control vs. 
PCS, p=0.09. (C) ammonia at 3 hours post-hepatectomy. Control vs. terlipressin, 
p=0.11. Control vs. PCS, p=0.03. (D) Lys-vasopressin at 3 hours post-hepatectomy. 
Control vs. terlipressin, p<0.0001. Control vs. PCS, p=0.50.  
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Fig. 4. The effects of terlipressin and portacaval shunt (PCS) on portal venous 
pressure (PVP) following 80% hepatectomy. (A) values represent median PVP of 
three 10 min intervals sampled for all pigs in each group processed using scale 
space analysis pre-hepatectomy (left), post-terlipressin or PCS but before 
hepatectomy (middle) and 1 hour post-hepatectomy (right). Hepatectomy alone 
(black), terlipressin + hepatectomy (blue) and PCS + hepatectomy (pink). Values in 
(B-E) represent mean ± standard deviation of representative 10 min intervals of PVP 
sampled out to 6 hours post hepatectomy, n=8 per group. * p<0.05 compared with 
control: (B) immediately post-hepatectomy (T0); (C) 1-2 h; (D) 3-4 h; (E) 5-6 h 
(Supplementary Table 1). 
values represent median PVP of three 10 min intervals sampled for all pigs in each 
group processed using scale space analysis 
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Fig. 5. The effects of terlipressin and portacaval shunt (PCS) on portal venous 
flow (PVF) following 80% hepatectomy. (A) Values represent median PVF of three 
10 min intervals sampled for all pigs in each group processed using scale space 
analysis pre-hepatectomy (left), post terlipressin or PCS but before hepatectomy 
(middle) and 1 hour post-hepatectomy (right). Hepatectomy alone (black), terlipressin 
+ hepatectomy (blue) and PCS + hepatectomy (pink). Values in (B-E) represent 
mean ± standard deviation of representative 10 min intervals of PVF sampled out to 
6 hours post hepatectomy, n=8 per group. * p<0.05 compared with control: (B) 
immediately post-hepatectomy (T0); (C) 1-2 h; (D) 3-4 h; (E) 5-6 h (Supplementary 
Table 2). 
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Fig. 6. The effects of terlipressin and portacaval shunt (PCS) on hepatic artery 
flow (HAF) following 80% hepatectomy. (A) Values represent median PVP of three 
10 min intervals sampled for all pigs in each group processed using scale space 
analysis pre-hepatectomy (left), post terlipressin or PCS but before hepatectomy 
(middle) and 1 hour post-hepatectomy (right). Hepatectomy alone (black), terlipressin 
+ hepatectomy (blue) and PCS + hepatectomy (pink). Values in (B-E) represent 
mean ± standard deviation of representative 10 min intervals of HAF sampled out to 
6 hours post hepatectomy, n=8 per group. * p<0.05 compared with control and ** 
p<0.05 compared with PCS: (B) immediately post-hepatectomy (T0); (C) 1-2 h; (D) 3-
4 h; (E) 5-6 h (Supplementary Table 3). 
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Clinical perspectives 
• Portal venous pressure can increase greatly after major liver resection, thereby 
increasing the risk of developing post-resection liver failure, which may be 
prevented by maintaining portal venous pressure in the normal range. 
• In this large animal study we demonstrate, for the first time, that terlipressin can 
prevent the increase in portal venous pressure after major liver resection in a large 
animal model. The effect of terlipressin was similar to that of portacaval shunting. 
• The role of terlipressin in preventing post-resection liver failure in humans merits 
investigation.  
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Supplementary data 
 
 
 
 
Supplementary Figure 1:  The study was undertaken in 3 phases. An acute pilot (not shown) 
and an acute terminal anesthetic series and a survival pilot. In the acute series there were 3 
groups with 8 pigs per group. Group 1 (control) underwent 80% hepatectomy alone, group 2 
(terlipressin) received terlipressin + 80% hepatectomy and group 3 (PCS) underwent direct 
portacaval shunting + 80% hepatectomy. All pigs were maintained under terminal anesthesia 
for up to 8 hours post-hepatectomy. Portal venous pressure (PVP), portal venous flow (PVF), 
hepatic artery flow (HAF) and mean arterial pressure (MAP) were recorded continuously. 
Blood samples (hourly) and liver biopsies (2 hourly) were collected for the duration and at 
termination of the study. In the survival pilot 8 pigs underwent 80% hepatectomy alone, 
were maintained for up to 7 days and underwent daily blood sampling and PVP and PVF 
measurement. 
 
Control = 80% 
hepatectomy 
alone
Terlipressin = 
terlipressin + 
80% 
hepatectomy
PCS = portacaval
shunt  + 80% 
hepatectomy
Resection
ResectionTerlipressinbolus
ResectionShunt
Terlipressin infusion
Continuous measurement of PVP, PVF, HAF and MAP with intermittent 
measurement of biochemistry for 8 h post-resection
n=8
n=8
n=8
Acute series
80% 
hepatectomy 
alone 
Resection
Daily measurement of PVP. PVF and biochemistry for up to 7 days  post-resection
n=8
Survival pilot
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Supplementary Figure 2: The effects of 80% hepatectomy on liver hemodynamics and 
biochemistry in the survival pilot study. A: portal venous pressure (PVP), B: portal venous 
flow (PVF), C: serum bilirubin, D: International Normalized Ratio (INR), E: serum aspartate 
transaminase (AST) and F: plasma ammonia were measured daily up to 5 days following 80% 
hepatectomy. Values represent mean ± standard deviation, n=8 per group.  
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Supplementary Table 1: Table of p values calculated by ANOVA for representative 10 min 
intervals of portal venous pressure for hepatectomy (control) vs. terlipressin and 
hepatectomy and for hepatectomy (control) vs. portacaval shunt and hepatectomy: 
immediately post-hepatectomy (T0); 0-1 h; 1-2 h; 2-3 h; 3-4 h; 4-5 h; 5-6 h; 6-7 h; and 7-8 h 
post-hepatectomy. 
 
Portal venous pressure 
interval 
Control vs. terlipressin 
and hepatectomy 
Control vs. portacaval 
shunt and 
hepatectomy 
T0 0.061 0.034 
0-1 h 0.046 0.025 
1-2 h 0.005 0.055 
2-3 h 0.012 0.028 
3-4 h 0.007 0.017 
4-5 h 0.005 0.287 
5-6 h 0.011 0.156 
6-7 h 0.017 0.287 
7-8 h 0.024 0.178 
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Supplementary Table 2: Table of p values calculated by ANOVA for representative 10 min 
intervals of portal venous flow for hepatectomy (control) vs. terlipressin and hepatectomy 
and for hepatectomy (control) vs. portacaval shunt and hepatectomy: immediately post-
hepatectomy (T0); 0-1 h; 1-2 h; 2-3 h; 3-4 h; 4-5 h; 5-6 h; 6-7 h; and 7-8 h post-hepatectomy. 
 
Portal venous flow 
interval 
Control vs. terlipressin 
and hepatectomy 
Control vs. portacaval 
shunt and 
hepatectomy 
T0 0.0006 0.0062 
0-1 h <0.0001 0.0022 
1-2 h 0.0005 0.0019 
2-3 h 0.0007 0.0015 
3-4 h 0.0055 0.0020 
4-5 h 0.0069 0.0037 
5-6 h 0.0025 0.0045 
6-7 h 0.0110 0.0037 
7-8 h 0.0005 0.0029 
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Supplementary Table 3: Table of p values calculated by ANOVA for representative 10 min 
intervals of hepatic artery flow for hepatectomy (control) vs. terlipressin and hepatectomy 
and for hepatectomy (control) vs. portacaval shunt and hepatectomy: immediately post-
hepatectomy (T0); 0-1 h; 1-2 h; 2-3 h; 3-4 h; 4-5 h; 5-6 h; 6-7 h; and 7-8 h post-hepatectomy. 
 
Hepatic artery flow 
interval 
Control vs. terlipressin 
and hepatectomy 
Control vs. portacaval 
shunt and 
hepatectomy 
T0 0.309 0.228 
0-1 hour 0.092 0.745 
1-2 hour 0.026 0.246 
2-3 hour 0.023 0.661 
3-4 hour 0.009 0.783 
4-5 hour 0.005 0.919 
5-6 hour 0.006 0.793 
6-7 hour 0.046 0.228 
7-8 hour 0.534 0.254 
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Supplementary Figure 3: Hematoxylin and eosin (H&E) staining was undertaken to 
characterize liver parenchymal injury following 80% hepatectomy in the acute series and 
survival pilot. (A) H&E × 20 of pig liver 6 hours following 80% hepatectomy alone 
demonstrating mild edema of portal tracts (P) and fresh hemorrhage into portal tracts and 
periportal liver cell plates (H). (B) H&E × 5 of pig liver 7 days following 80% hepatectomy 
alone demonstrating islands of hepatocellular necrosis with bile impregnation (N). (C) H&E × 
20 of pig liver 7 days following 80% hepatectomy alone demonstrating a normal portal tract, 
and mild hepatocyte steatosis. The edge of a necrotic area (NA) is present at the top right 
corner.  
